Back to ELV Overview
NYQ · Valuation Lab
ELV
Elevance Health, Inc.
Last$391.24
Market cap84.8B
EV/EBITDA9.2x
Intrinsic value
$466.57
MoS +16.1% · Fairly Valued
Assuming 2.1% FCF margin and 1.4% Y1–5 growth.
Upside to price
EV (DCF)94.7B
Terminal share66%
Expected IV$609.71
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 66% of EV
PV of stage FCFs32.4B
PV of terminal value62.3B
Enterprise value94.7B
Net cash / (debt)6.5B
Equity value101.2B
Intrinsic value / share$466.57
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 203.9B | 4.3B | 4B | 93.7% |
| Y2 | 206.8B | 4.3B | 3.8B | 87.7% |
| Y3 | 209.7B | 4.4B | 3.6B | 82.2% |
| Y4 | 212.6B | 4.5B | 3.4B | 76.9% |
| Y5 | 215.6B | 4.5B | 3.3B | 72.1% |
| Y6 | 219.9B | 4.6B | 3.1B | 67.5% |
| Y7 | 224.3B | 4.7B | 3B | 63.2% |
| Y8 | 228.8B | 4.8B | 2.8B | 59.2% |
| Y9 | 233.4B | 4.9B | 2.7B | 55.5% |
| Y10 | 238B | 5B | 2.6B | 51.9% |
| Terminal | — | — | 62.3B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.